Summary of bluebird bio, Inc. (NASDAQ:BLUE) Ratings as of Nov 10, 2018

November 10, 2018 - By Mike Johnson

bluebird bio, Inc. (NASDAQ:BLUE) Corporate Logo
During 2018 Q2 the big money sentiment increased to 1.4. That’s change of 0.41, from 2018Q1’s 0.99. 36 investors sold all, 69 reduced holdings as bluebird bio, Inc. ratio increased. 98 rose positions while 49 funds took positions. Funds hold 51.83 million shares thus 0.73% more from 2018Q1’s 51.45 million shares.
Envestnet Asset Mngmt owns 387 shs. Ghost Tree Capital Limited Liability Company, New York-based fund reported 105,000 shs. Orbimed Advsr Lc stated it has 0.91% of its capital in bluebird bio, Inc. (NASDAQ:BLUE). Moreover, Trust Com Of Vermont has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE) for 111 shs. Pictet Asset Mngmt Ltd reported 155,568 shs or 0.06% of all its holdings. Benjamin F Edwards Co invested in 0% or 81 shs. Mckinley Capital Management Lc Delaware has invested 0.02% of its capital in bluebird bio, Inc. (NASDAQ:BLUE). Kbc Nv holds 0.02% of its capital in bluebird bio, Inc. (NASDAQ:BLUE) for 11,168 shs. Eaton Vance Management stated it has 14,429 shs. Capital Ca holds 0.38% of its capital in bluebird bio, Inc. (NASDAQ:BLUE) for 15,775 shs. Highland Cap Management Lp invested in 0.02% or 2,000 shs. Stanley has 4,368 shs. Tokio Marine Asset Management Limited holds 0.45% or 15,800 shs. Congress Asset Ma reported 0.01% stake. Franklin Res Inc holds 0.03% or 388,400 shs in its capital.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

In total 9 analysts cover Bluebird Bio (NASDAQ:BLUE). “Buy” rating has 6, “Sell” are 1, while 2 are “Hold”. 67% are bullish. 12 are the (NASDAQ:BLUE)’s analyst reports since May 30, 2018 according to StockzIntelligence Inc. On Tuesday, June 19 Evercore upgraded the shares of BLUE in report to “Outperform” rating. On Sunday, June 3 the company was maintained by Cantor Fitzgerald. On Friday, June 15 the firm earned “Buy” rating by BTIG Research. On Monday, November 5 Morgan Stanley maintained bluebird bio, Inc. (NASDAQ:BLUE) rating. Morgan Stanley has “Equal-Weight” rating and $185 target. On Monday, June 4 Oppenheimer maintained bluebird bio, Inc. (NASDAQ:BLUE) with “Hold” rating. On Thursday, May 31 PiperJaffray reinitiated the shares of BLUE in report with “Overweight” rating. On Monday, October 15 the firm has “Equal-Weight” rating by Morgan Stanley given. On Monday, November 5 the rating was upgraded by Janney Capital to “Buy”. On Friday, June 1 the stock has “Buy” rating by BTIG Research. On Friday, June 15 the rating was maintained by Oppenheimer with “Hold”. Listed here are bluebird bio, Inc. (NASDAQ:BLUE) PTs and latest ratings.

05/11/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $186 New Target: $185 Maintain
05/11/2018 Broker: Wedbush Old Rating: Outperform New Rating: Outperform Old Target: $204 New Target: $166 Maintain
05/11/2018 Broker: Janney Capital Old Rating: Neutral New Rating: Buy Old Target: $170 New Target: $170 Upgrade
15/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $190 New Target: $186 Maintain
15/06/2018 Broker: BTIG Research Rating: Buy New Target: $250.0000 Maintain
15/06/2018 Broker: Oppenheimer Rating: Hold Maintain
19/06/2018 Broker: Evercore Old Rating: In-Line New Rating: Outperform Old Target: $175 New Target: $230 Upgrade
04/06/2018 Broker: Oppenheimer Rating: Hold Maintain
03/06/2018 Broker: Cantor Fitzgerald Rating: Sell New Target: $122.0000 Maintain
01/06/2018 Broker: BTIG Research Rating: Buy New Target: $250.0000 Maintain

BLUE is touching $126.33 during the last trading session, after decreased 4.60%.Currently bluebird bio, Inc. is uptrending after 15.36% change in last November 10, 2017. BLUE has also 632,558 shares volume. BLUE underperformed by 0.26% the S&P 500.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.The firm is valued at $6.91 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent beta-thalassemia, and severe sickle cell disease.Last it reported negative earnings. The companyÂ’s lead product candidate is bb2121, a chimeric antigen receptor T cell product candidate that is in Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus; and Medigene AG for the research and development of TCR product candidates directed against approximately four antigens for the treatment of cancer indications.

For more bluebird bio, Inc. (NASDAQ:BLUE) news published briefly go to: Fool.com, Seekingalpha.com, Benzinga.com, Fool.com or Nasdaq.com. The titles are as follows: “Here’s Why bluebird bio Fell 21.4% in October” published on November 08, 2018, “bluebird bio, Inc. (BLUE) CEO Nick Leschly on Q3 2018 Results – Earnings Call Transcript” on November 02, 2018, “Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation” with a publish date: November 05, 2018, “3 Top Biotech Stocks to Buy in November” and the last “3 Cancer Stocks to Watch in December” with publication date: November 07, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.